Rotational thrombelastometry in oral anticoagulants

Rotational thrombelastometry in oral anticoagulants - ROAK

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012821

Enrollment

Registered

2018-01-11

Start date

2017-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D68

Interventions

Group 1: The new oral anticoagulants dabigatran and rivaroxaban are to be investigated by means of rotational thromboelastometry/thromboelastography. For this purpose, new tests are available, which s

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Written consent 2. Age >18 years

Exclusion criteria

Exclusion criteria: 1. Myelodysplastic syndrome 2. Thrombopenia 3. Hereditary coagulation diseases

Design outcomes

Primary

Measure	Time frame
Changes in ROTEM-variables in EXTEM, NATEM, ECATEM und FIBTEM in comparison to blood samples without Rivaroxaban/Dabigatran	—

Secondary

Measure	Time frame
Changes in ROTEM-variables ECATEM and diluted tissue factor test with and without substance specific catcher.	—

Countries

Germany

Contacts

Public ContactSimon Schäfer

Klinik für AnästhesiologieKlinikum der Universität MünchenLudwig-Maximilians-Universität

simon.schaefer@med.uni-muenchen.de+49 (0)89 4400 - 131 81142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026